MinervaX Commences First Phase 1 Clinical Study of Novel GBS Vaccine in Older Adults
- Expands development of novel GBS vaccine in older adult population
- Targeting significant and growing unmet medical need of GBS infection
Copenhagen, Denmark, 17 April 2023 – MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), announces the first phase 1 clinical study in older adults of its novel GBS vaccine, at CEVAC (Centre for Vaccinology) in Ghent, Belgium.
